% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Walther:307536,
      author       = {D. Walther and J. Ernst and C. Wollenhaupt and S. Wittig
                      and M. Härtel and G. Brodt and T. Milde$^*$ and B. Gruhn},
      title        = {{E}fficacy and {S}afety of {D}onor {L}ymphocyte {I}nfusion
                      {A}fter {A}llogeneic {H}ematopoietic {S}tem {C}ell
                      {T}ransplantation in {P}ediatric {P}atients.},
      journal      = {European journal of haematology},
      volume       = {nn},
      issn         = {0902-4441},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2026-00041},
      pages        = {nn},
      year         = {2026},
      note         = {epub},
      abstract     = {This retrospective study evaluates the efficacy and safety
                      of donor lymphocyte infusion (DLI) after allogeneic
                      hematopoietic stem cell transplantation (HSCT) in children.
                      We describe the long-term use of preemptive, prophylactic,
                      and therapeutic DLI with a gradual dose increase in half-log
                      increments. Under close monitoring, we increased the DLI
                      dose only in patients that did not show signs of
                      graft-versus-host disease (GVHD). In the preemptive cohort,
                      10 of 12 patients $(83\%)$ with minimal residual disease
                      (MRD) positivity remained relapse-free. Among 11 patients
                      with genetic diseases and mixed chimerism, nine $(82\%)$
                      responded to preemptive DLI. Six patients $(100\%)$ of the
                      prophylactic cohort with a very high risk of relapse had a
                      successful outcome without relapse or GVHD. Three of the
                      five patients $(60\%)$ of the therapeutic cohort were
                      successfully treated with DLI. We observed acute GVHD (grade
                      I and II) in only two patients $(6\%).$ The results of our
                      study indicate that the long-term use of DLI is a promising
                      strategy and can effectively prevent relapse, graft
                      rejection, and even cure relapse. The observed low rate of
                      GVHD may be attributed to the gradual dose increase.
                      Therefore, we consider DLI a safe and effective therapeutic
                      option.},
      keywords     = {donor chimerism (Other) / donor lymphocyte infusion (Other)
                      / graft‐versus‐host disease (Other) /
                      graft‐versus‐leukemia effect (Other) / hematopoietic
                      stem cell transplantation (Other)},
      cin          = {B310},
      ddc          = {610},
      cid          = {I:(DE-He78)B310-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41489018},
      doi          = {10.1111/ejh.70112},
      url          = {https://inrepo02.dkfz.de/record/307536},
}